^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Tukysa (tucatinib) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of monoclonal antibodies and tyrosine kinase inhibitors in advanced breast carcinoma.
Published date:
05/26/2022
Excerpt:
...phase III trials incorporating TKIs such as Neratinib (NER) and Tucatinib (TUC), there was improved OS (21m Vs 18.7, 24.7m Vs 19.2m respectively) as compared to Standard of care and chemotherapy….Both monoclonal antibodies and tyrosine kinase inhibitors show clinically significant benefits in advanced HER2 positive breast carcinoma.
DOI:
10.1200/JCO.2022.40.16_suppl.e13017
Source:
Title:
Imaging molecular alterations during tucatinib response in preclinical models of HER2+ breast cancer Add to My Itinerary
Published date:
03/15/2023
Excerpt:
Tucatinib treated BT474 and BCM3472 tumors had a 2.07 and 2.63 fold decrease in tumor volume, respectively (p<0.01). Tucatinib treated BT474 and BCM3472 tumors had significantly decreased hypoxia and proliferation, relative to control tumors (p<0.05)...Tucatinib significantly decreases tumor volume and decreases intratumoral proliferation and hypoxia in both cell-line and patient-derived xenograft models of HER2+ breast cancer.
Source:
Title:
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies
Published date:
05/04/2022
Excerpt:
Single-agent tucatinib induced tumor regressions in xenograft models of HER2+ breast cancer and combination with trastuzumab induced a complete and sustained blockade of HER2/PI3K/AKT signaling. Efficacy of the tucatinib/trastuzumab combination matched that induced by current standard-of-care trastuzumab/pertuzumab/docetaxel combination...
DOI:
10.1158/1535-7163.MCT-21-0847
Source:
Title:
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Published date:
04/13/2022
Excerpt:
Within the HER2+ population, tucatinib response tracked strongly with HER2-driven signaling. Single-agent tucatinib induced tumor regressions in xenograft models of HER2+ breast cancer and combination with trastuzumab...In xenograft models of HER2+ breast cancer that also express estrogen receptor (ER; HER2+/ER+), tucatinib showed combined efficacy with inhibitors of CDK4/6 and ER, indicating potential novel therapeutic strategies for difficult-to-treat subtypes of HER2+ breast cancer.
DOI:
https://doi.org/10.1158/1535-7163.MCT-21-0847
Source:
Title:
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Published date:
01/21/2021
Excerpt:
CONTRADICTING EVIDENCE:...The anti-proliferative effects of neratinib, lapatinib, and tucatinib were examined across a panel of 115 cancer cell lines...The MDA-MB-453 cell line was the only HER2+ cell line that had a poor response to each TKI.
DOI:
10.1038/s41416-020-01257-x
Source:
Title:
Abstract 1962: Preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors
Published date:
05/15/2020
Excerpt:
These data demonstrate that tucatinib is a uniquely selective and highly potent inhibitor of HER2 signaling, with activity against HER2+ breast cancer xenograft and brain metastasis models...These preclinical findings are consistent with clinical data showing tucatinib activity in patients with HER2+ MBC with brain metastases and support the continued development of tucatinib in patients with HER2+ BC.
DOI:
10.1158/1538-7445.AM2020-1962
